ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Microbiome firms in new partnerships

by Ann M. Thayer
July 18, 2016 | APPEARED IN VOLUME 94, ISSUE 29

Evelo Biosciences and Epiva Biosciences, two-year-old microbiome companies launched by Flagship Ventures, have merged. Keeping the Evelo name, the new 42-person company is targeting cancer, autoimmune, and inflammatory disease therapies. To date, Flagship has invested $40 million in the business. Separately, Seres Therapeutics, a Flagship-backed microbiome therapeutics firm that went public in 2015, will collaborate with Emulate, a developer of organs-on-a-chip technology. They will advance an intestine-chip system that Seres plans to use.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment